Burning Rock Biotech (BNR) Cash & Current Investments (2019 - 2025)

Burning Rock Biotech's Cash & Current Investments history runs 7 years deep, the most recent figure standing at $67.8 million for Q4 2025.

• In Q4 2025, Cash & Current Investments fell 6.69% year-over-year to $67.8 million; the TTM figure through Dec 2025 stood at $67.8 million (down 6.69% YoY), while the FY2025 annual figure was $68.2 million, down 4.65% from the prior year.
• Cash & Current Investments was $67.8 million for Q4 2025 at Burning Rock Biotech, up from $65.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $322.5 million in Q1 2021 to a low of $63.2 million in Q2 2025.
• Historically, Cash & Current Investments has averaged $135.4 million across 5 years, with a median of $96.0 million in 2023.
• The sharpest annual moves came in 2021 and 2022: Cash & Current Investments surged 517.38% in 2021, then tumbled 44.32% in 2022.
• A 5-year view of Cash & Current Investments shows it stood at $225.1 million in 2021, then plunged by 42.2% to $130.1 million in 2022, then slumped by 34.32% to $85.4 million in 2023, then declined by 14.92% to $72.7 million in 2024, then declined by 6.69% to $67.8 million in 2025.
• The last three Cash & Current Investments figures came in at $67.8 million (Q4 2025), $65.7 million (Q3 2025), and $63.2 million (Q2 2025), per Business Quant data.